In June, Owkin and world-leading Cancer research institutions and technology companies from the US, France, Germany, and Switzerland unveiled MOSAIC, a $50 million initiative to use spatial omics technologies at unprecedented scale. The aim is to analyze the tumor microenvironment of more than a thousand patients in each of seven difficult-to-treat cancers and to develop and apply AI/ML tools to develop a spatial omics atlas that will help to advance novel therapies. In this session, we will present the scientific vision, the aims and role of participating institutions, and an update on progress in the project's first six busy months.

With thirty years of experience in informatics and data and big pharma positions at Roche and AstraZeneca, Bryn Roberts has a unique perspective on the data-growing pains now facing life sciences. Within life sciences organizations, there are both responsibilities and privileges associated with data production and use, he says. Data producers should share data within certain parameters, and data consumers should use and credit data fairly, he believes. In this fireside chat, Stan will interview Bryn who will share his insights into the state of data right now in life sciences, why data citizenship is the paradigm shift we all need to embrace, how to truly create a FAIR data culture, and how artificial intelligence and machine learning will most impactfully change our data landscape.

Barts Health NHS Trust and Queen Mary University of London (QMUL) are embarking on one of the world's most ambitious digital medicine initiatives. Director of the NIHR Barts Biomedical Research Centre, Prof Mark Caulfield, and newly appointed QMUL Honorary Professor Tom Chittenden will lay out this vision and its impact on patients and science. In one of the largest and most diverse NHS trusts, in the heart of the East London AI and medical research community, Barts and QMUL are investing £600m pounds to create new digital healthcare infrastructure and develop a world-leading open-access exascale causal AI computing platform. This will enable a newly detailed understanding of the biology of cancer, cardiovascular, and other diseases, driving cutting-edge drug and digital health development relevant to people of every continental ancestry. These assets will deliver the most advanced digital precision medicine to millions of people in local communities, and, through research and industry partnerships, to people and patients worldwide.